Concepts (244)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Antifungal Agents | 10 | 2024 | 286 | 4.010 |
Why?
|
| Onychomycosis | 6 | 2016 | 7 | 3.100 |
Why?
|
| Skin Neoplasms | 15 | 2025 | 798 | 2.700 |
Why?
|
| Foot Dermatoses | 4 | 2016 | 7 | 2.090 |
Why?
|
| Public Health | 3 | 2024 | 260 | 1.950 |
Why?
|
| Sexually Transmitted Diseases | 3 | 2024 | 93 | 1.750 |
Why?
|
| Melanoma | 7 | 2025 | 824 | 1.640 |
Why?
|
| Carcinoma, Basal Cell | 4 | 2019 | 71 | 1.320 |
Why?
|
| Keratosis, Actinic | 4 | 2020 | 12 | 1.270 |
Why?
|
| Skin Diseases | 2 | 2023 | 124 | 1.100 |
Why?
|
| Tinea | 2 | 2016 | 6 | 1.040 |
Why?
|
| Dermatology | 2 | 2022 | 34 | 1.030 |
Why?
|
| Candidiasis, Oral | 1 | 2024 | 2 | 0.970 |
Why?
|
| Vulvar Neoplasms | 1 | 2025 | 17 | 0.960 |
Why?
|
| Felty Syndrome | 1 | 2023 | 2 | 0.900 |
Why?
|
| Hand Dermatoses | 1 | 2023 | 7 | 0.900 |
Why?
|
| Sweet Syndrome | 1 | 2023 | 11 | 0.890 |
Why?
|
| Dermatitis | 1 | 2023 | 25 | 0.890 |
Why?
|
| Crows | 1 | 2022 | 1 | 0.820 |
Why?
|
| Fungemia | 1 | 2022 | 22 | 0.810 |
Why?
|
| Skin Lightening Preparations | 1 | 2022 | 1 | 0.810 |
Why?
|
| Invasive Fungal Infections | 1 | 2022 | 13 | 0.800 |
Why?
|
| Administration, Cutaneous | 8 | 2020 | 66 | 0.790 |
Why?
|
| Neutropenia | 1 | 2023 | 202 | 0.790 |
Why?
|
| Impetigo | 2 | 2018 | 5 | 0.780 |
Why?
|
| Lipoma | 1 | 2021 | 23 | 0.750 |
Why?
|
| Quinolones | 2 | 2018 | 54 | 0.750 |
Why?
|
| Muscle Neoplasms | 1 | 2021 | 21 | 0.750 |
Why?
|
| Aminopyridines | 2 | 2018 | 53 | 0.740 |
Why?
|
| Doxycycline | 2 | 2020 | 115 | 0.730 |
Why?
|
| Catheterization, Central Venous | 1 | 2022 | 132 | 0.730 |
Why?
|
| Catheterization, Peripheral | 1 | 2022 | 126 | 0.710 |
Why?
|
| Travel-Related Illness | 1 | 2020 | 3 | 0.700 |
Why?
|
| Spotted Fever Group Rickettsiosis | 1 | 2020 | 4 | 0.700 |
Why?
|
| Rickettsia Infections | 1 | 2020 | 6 | 0.700 |
Why?
|
| Rickettsia | 1 | 2020 | 11 | 0.690 |
Why?
|
| Diterpenes | 1 | 2020 | 28 | 0.680 |
Why?
|
| Masks | 1 | 2020 | 38 | 0.680 |
Why?
|
| Dermatologic Agents | 1 | 2020 | 31 | 0.670 |
Why?
|
| Soft Tissue Neoplasms | 1 | 2021 | 130 | 0.670 |
Why?
|
| Refusal to Treat | 1 | 2019 | 9 | 0.670 |
Why?
|
| Anti-Bacterial Agents | 5 | 2020 | 2397 | 0.660 |
Why?
|
| Leukemia, Prolymphocytic, T-Cell | 1 | 2019 | 2 | 0.660 |
Why?
|
| Disease Transmission, Infectious | 1 | 2020 | 86 | 0.660 |
Why?
|
| Erythema | 1 | 2019 | 24 | 0.650 |
Why?
|
| Nail Biting | 1 | 2019 | 4 | 0.640 |
Why?
|
| Free Radical Scavengers | 1 | 2019 | 49 | 0.630 |
Why?
|
| Treatment Refusal | 1 | 2019 | 77 | 0.630 |
Why?
|
| BRCA1 Protein | 1 | 2019 | 67 | 0.630 |
Why?
|
| Trichotillomania | 1 | 2019 | 34 | 0.620 |
Why?
|
| Clinical Trials as Topic | 3 | 2024 | 1084 | 0.620 |
Why?
|
| Standard of Care | 1 | 2019 | 129 | 0.620 |
Why?
|
| Acetylcysteine | 1 | 2019 | 73 | 0.610 |
Why?
|
| Neoplastic Syndromes, Hereditary | 1 | 2019 | 70 | 0.610 |
Why?
|
| Humans | 48 | 2025 | 123311 | 0.610 |
Why?
|
| Triazoles | 5 | 2016 | 138 | 0.600 |
Why?
|
| Practice Guidelines as Topic | 1 | 2025 | 1259 | 0.590 |
Why?
|
| Cheek | 1 | 2017 | 24 | 0.550 |
Why?
|
| Facial Neoplasms | 1 | 2017 | 19 | 0.550 |
Why?
|
| Rosacea | 2 | 2024 | 14 | 0.540 |
Why?
|
| Leishmaniasis, Cutaneous | 1 | 2017 | 48 | 0.540 |
Why?
|
| Informed Consent | 1 | 2019 | 342 | 0.530 |
Why?
|
| Boron Compounds | 4 | 2016 | 33 | 0.510 |
Why?
|
| Bridged Bicyclo Compounds, Heterocyclic | 4 | 2016 | 39 | 0.510 |
Why?
|
| Streptococcal Infections | 1 | 2018 | 244 | 0.500 |
Why?
|
| Aminoquinolines | 3 | 2010 | 35 | 0.500 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 358 | 0.480 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 374 | 0.470 |
Why?
|
| United States | 9 | 2025 | 10667 | 0.460 |
Why?
|
| Biopsy | 3 | 2019 | 1236 | 0.460 |
Why?
|
| Carcinoma, Squamous Cell | 2 | 2017 | 651 | 0.460 |
Why?
|
| Staphylococcal Infections | 1 | 2018 | 552 | 0.430 |
Why?
|
| Pandemics | 1 | 2020 | 1101 | 0.410 |
Why?
|
| Head and Neck Neoplasms | 1 | 2017 | 481 | 0.400 |
Why?
|
| Diagnosis, Differential | 4 | 2021 | 1877 | 0.380 |
Why?
|
| Consensus | 2 | 2024 | 610 | 0.370 |
Why?
|
| Pyridones | 3 | 2016 | 112 | 0.360 |
Why?
|
| Skin Diseases, Parasitic | 2 | 2010 | 5 | 0.360 |
Why?
|
| Psoriasis | 2 | 2024 | 45 | 0.360 |
Why?
|
| Middle Aged | 13 | 2025 | 26075 | 0.350 |
Why?
|
| Obsessive-Compulsive Disorder | 1 | 2019 | 772 | 0.350 |
Why?
|
| Skin Diseases, Infectious | 1 | 2010 | 24 | 0.350 |
Why?
|
| Hot Temperature | 1 | 2010 | 136 | 0.340 |
Why?
|
| Skin Diseases, Bacterial | 2 | 2010 | 23 | 0.340 |
Why?
|
| Toll-Like Receptor 7 | 1 | 2009 | 8 | 0.330 |
Why?
|
| Prevalence | 3 | 2025 | 2407 | 0.330 |
Why?
|
| Genetic Predisposition to Disease | 1 | 2019 | 3081 | 0.300 |
Why?
|
| Azithromycin | 1 | 2008 | 44 | 0.300 |
Why?
|
| Treatment Outcome | 10 | 2024 | 12168 | 0.300 |
Why?
|
| Dysplastic Nevus Syndrome | 2 | 2017 | 21 | 0.290 |
Why?
|
| Aged, 80 and over | 7 | 2025 | 6387 | 0.290 |
Why?
|
| Aged | 10 | 2025 | 19174 | 0.290 |
Why?
|
| Male | 17 | 2023 | 60285 | 0.280 |
Why?
|
| Silicone Gels | 1 | 2006 | 3 | 0.280 |
Why?
|
| Granuloma, Foreign-Body | 1 | 2006 | 10 | 0.270 |
Why?
|
| Health Knowledge, Attitudes, Practice | 1 | 2013 | 828 | 0.270 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2006 | 63 | 0.270 |
Why?
|
| Cosmetic Techniques | 1 | 2006 | 11 | 0.270 |
Why?
|
| Entamoebiasis | 1 | 2006 | 3 | 0.270 |
Why?
|
| Entamoeba histolytica | 1 | 2006 | 17 | 0.260 |
Why?
|
| Delphi Technique | 2 | 2024 | 203 | 0.260 |
Why?
|
| Naphthalenes | 2 | 2016 | 37 | 0.260 |
Why?
|
| Antineoplastic Agents | 2 | 2019 | 1662 | 0.260 |
Why?
|
| Skin | 3 | 2021 | 507 | 0.250 |
Why?
|
| Female | 14 | 2025 | 65618 | 0.250 |
Why?
|
| Administration, Topical | 4 | 2015 | 141 | 0.240 |
Why?
|
| Acupuncture Therapy | 1 | 2024 | 11 | 0.240 |
Why?
|
| Dielectric Spectroscopy | 1 | 2024 | 3 | 0.240 |
Why?
|
| Condylomata Acuminata | 2 | 2018 | 15 | 0.240 |
Why?
|
| Pruritus | 1 | 2024 | 41 | 0.240 |
Why?
|
| Anti-Infective Agents, Local | 2 | 2015 | 70 | 0.240 |
Why?
|
| Algorithms | 2 | 2024 | 1599 | 0.230 |
Why?
|
| Complementary Therapies | 1 | 2024 | 41 | 0.230 |
Why?
|
| Filgrastim | 1 | 2023 | 15 | 0.230 |
Why?
|
| Adult | 11 | 2025 | 29087 | 0.220 |
Why?
|
| Blister | 1 | 2023 | 19 | 0.220 |
Why?
|
| Tumor Necrosis Factor-alpha | 1 | 2006 | 667 | 0.220 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2006 | 767 | 0.220 |
Why?
|
| Immunoglobulin G | 1 | 2006 | 769 | 0.220 |
Why?
|
| Gynecology | 1 | 2025 | 127 | 0.220 |
Why?
|
| Dermatomycoses | 2 | 2015 | 15 | 0.210 |
Why?
|
| Mohs Surgery | 2 | 2024 | 42 | 0.210 |
Why?
|
| Double-Blind Method | 5 | 2018 | 1600 | 0.200 |
Why?
|
| Philippines | 1 | 2022 | 23 | 0.200 |
Why?
|
| Skin Pigmentation | 1 | 2022 | 26 | 0.200 |
Why?
|
| Drug Resistance, Fungal | 1 | 2022 | 24 | 0.200 |
Why?
|
| Recurrence | 2 | 2016 | 1419 | 0.200 |
Why?
|
| Asia | 1 | 2022 | 107 | 0.190 |
Why?
|
| Molluscum Contagiosum | 1 | 2021 | 11 | 0.190 |
Why?
|
| Candida | 1 | 2022 | 75 | 0.190 |
Why?
|
| Young Adult | 5 | 2025 | 8871 | 0.190 |
Why?
|
| Scapula | 1 | 2021 | 12 | 0.190 |
Why?
|
| India | 1 | 2022 | 217 | 0.190 |
Why?
|
| Dermatitis, Atopic | 1 | 2021 | 41 | 0.190 |
Why?
|
| Incidence | 2 | 2025 | 3052 | 0.180 |
Why?
|
| Zimbabwe | 1 | 2020 | 10 | 0.180 |
Why?
|
| Skin Ulcer | 1 | 2020 | 32 | 0.170 |
Why?
|
| Nucleic Acid Amplification Techniques | 1 | 2020 | 66 | 0.170 |
Why?
|
| Surgeons | 1 | 2024 | 247 | 0.170 |
Why?
|
| Dermatologists | 1 | 2019 | 3 | 0.170 |
Why?
|
| Drug Administration Schedule | 3 | 2018 | 725 | 0.170 |
Why?
|
| Serologic Tests | 1 | 2020 | 117 | 0.170 |
Why?
|
| Back | 1 | 2019 | 11 | 0.170 |
Why?
|
| Off-Label Use | 1 | 2019 | 25 | 0.160 |
Why?
|
| Occupational Exposure | 1 | 2020 | 128 | 0.160 |
Why?
|
| Human papillomavirus 11 | 1 | 2018 | 2 | 0.160 |
Why?
|
| Human papillomavirus 6 | 1 | 2018 | 3 | 0.160 |
Why?
|
| Skin Cream | 1 | 2018 | 5 | 0.160 |
Why?
|
| Patient Transfer | 1 | 2019 | 101 | 0.150 |
Why?
|
| Neck | 1 | 2019 | 138 | 0.150 |
Why?
|
| Hydrogels | 1 | 2018 | 78 | 0.150 |
Why?
|
| Streptococcus pyogenes | 1 | 2018 | 77 | 0.150 |
Why?
|
| Nevus, Pigmented | 1 | 2017 | 32 | 0.140 |
Why?
|
| Nevus | 1 | 2016 | 35 | 0.140 |
Why?
|
| Tinea Pedis | 1 | 2016 | 1 | 0.130 |
Why?
|
| Europe | 2 | 2018 | 351 | 0.130 |
Why?
|
| Cross-Sectional Studies | 1 | 2025 | 3382 | 0.130 |
Why?
|
| Itraconazole | 1 | 2016 | 24 | 0.130 |
Why?
|
| Evidence-Based Medicine | 1 | 2020 | 625 | 0.130 |
Why?
|
| Clinical Trials, Phase III as Topic | 1 | 2016 | 67 | 0.130 |
Why?
|
| Fluconazole | 1 | 2016 | 47 | 0.130 |
Why?
|
| Referral and Consultation | 1 | 2019 | 530 | 0.130 |
Why?
|
| Drug Resistance, Bacterial | 1 | 2018 | 361 | 0.120 |
Why?
|
| Pharmaceutical Solutions | 1 | 2015 | 8 | 0.120 |
Why?
|
| Imidazoles | 1 | 2016 | 193 | 0.120 |
Why?
|
| Age Distribution | 1 | 2016 | 410 | 0.120 |
Why?
|
| Diabetes Complications | 1 | 2016 | 196 | 0.120 |
Why?
|
| Administration, Oral | 1 | 2016 | 669 | 0.110 |
Why?
|
| Retrospective Studies | 3 | 2025 | 16066 | 0.110 |
Why?
|
| Antiviral Agents | 1 | 2018 | 744 | 0.110 |
Why?
|
| Sunscreening Agents | 1 | 2013 | 4 | 0.110 |
Why?
|
| Sunlight | 1 | 2013 | 23 | 0.110 |
Why?
|
| Margins of Excision | 3 | 2017 | 51 | 0.110 |
Why?
|
| Child | 6 | 2021 | 24264 | 0.100 |
Why?
|
| Australia | 1 | 2013 | 139 | 0.100 |
Why?
|
| Patient Compliance | 1 | 2016 | 470 | 0.100 |
Why?
|
| Patient Education as Topic | 1 | 2016 | 453 | 0.100 |
Why?
|
| Infant | 3 | 2018 | 12379 | 0.100 |
Why?
|
| Patient Selection | 1 | 2016 | 684 | 0.100 |
Why?
|
| Physician-Patient Relations | 1 | 2016 | 428 | 0.100 |
Why?
|
| Child, Preschool | 3 | 2018 | 13916 | 0.100 |
Why?
|
| Ultraviolet Rays | 1 | 2013 | 204 | 0.100 |
Why?
|
| Biopsy, Needle | 1 | 2012 | 229 | 0.100 |
Why?
|
| Research Design | 1 | 2015 | 679 | 0.090 |
Why?
|
| Porokeratosis | 1 | 2010 | 2 | 0.090 |
Why?
|
| Risk Assessment | 1 | 2020 | 3337 | 0.090 |
Why?
|
| Comorbidity | 1 | 2016 | 1498 | 0.090 |
Why?
|
| Antimetabolites | 1 | 2010 | 33 | 0.090 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2016 | 1118 | 0.090 |
Why?
|
| Neoplasm Invasiveness | 1 | 2012 | 604 | 0.090 |
Why?
|
| Skin Diseases, Viral | 1 | 2010 | 4 | 0.090 |
Why?
|
| Adolescent | 4 | 2018 | 19132 | 0.090 |
Why?
|
| Fluorouracil | 1 | 2010 | 128 | 0.090 |
Why?
|
| Cryotherapy | 1 | 2010 | 25 | 0.090 |
Why?
|
| Disease-Free Survival | 1 | 2012 | 859 | 0.090 |
Why?
|
| Risk Factors | 2 | 2016 | 10042 | 0.090 |
Why?
|
| Hyperthermia, Induced | 1 | 2010 | 45 | 0.090 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 3549 | 0.080 |
Why?
|
| Immunologic Factors | 1 | 2010 | 179 | 0.080 |
Why?
|
| Minocycline | 1 | 2008 | 36 | 0.080 |
Why?
|
| Dermatitis, Seborrheic | 1 | 2007 | 3 | 0.070 |
Why?
|
| Ketoconazole | 1 | 2007 | 10 | 0.070 |
Why?
|
| Adjuvants, Immunologic | 1 | 2010 | 376 | 0.070 |
Why?
|
| Precancerous Conditions | 1 | 2010 | 284 | 0.070 |
Why?
|
| Survival Rate | 1 | 2012 | 2001 | 0.070 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2024 | 1078 | 0.070 |
Why?
|
| Mass Screening | 1 | 2013 | 788 | 0.070 |
Why?
|
| Transsexualism | 1 | 2006 | 11 | 0.070 |
Why?
|
| Etanercept | 1 | 2006 | 38 | 0.070 |
Why?
|
| Injections, Subcutaneous | 1 | 2006 | 126 | 0.070 |
Why?
|
| Thigh | 1 | 2006 | 50 | 0.070 |
Why?
|
| Anal Canal | 1 | 2006 | 79 | 0.060 |
Why?
|
| Aging | 1 | 2013 | 1183 | 0.060 |
Why?
|
| Case-Control Studies | 1 | 2012 | 3240 | 0.060 |
Why?
|
| Papillomavirus Infections | 1 | 2009 | 284 | 0.060 |
Why?
|
| Animals | 2 | 2022 | 33822 | 0.060 |
Why?
|
| Capsaicin | 1 | 2024 | 17 | 0.060 |
Why?
|
| Penicillins | 1 | 2005 | 154 | 0.060 |
Why?
|
| Cephalosporins | 1 | 2005 | 138 | 0.060 |
Why?
|
| Drug Hypersensitivity | 1 | 2005 | 96 | 0.060 |
Why?
|
| Structure-Activity Relationship | 1 | 2005 | 569 | 0.060 |
Why?
|
| Disease Outbreaks | 1 | 2006 | 321 | 0.060 |
Why?
|
| Severity of Illness Index | 3 | 2018 | 2852 | 0.050 |
Why?
|
| Prognosis | 2 | 2024 | 4515 | 0.050 |
Why?
|
| Cantharidin | 1 | 2021 | 1 | 0.050 |
Why?
|
| Curettage | 1 | 2021 | 6 | 0.050 |
Why?
|
| Global Health | 1 | 2006 | 546 | 0.050 |
Why?
|
| Dosage Forms | 2 | 2010 | 9 | 0.040 |
Why?
|
| Russia | 1 | 2018 | 39 | 0.040 |
Why?
|
| South Africa | 1 | 2018 | 99 | 0.040 |
Why?
|
| Dermoscopy | 1 | 2017 | 2 | 0.040 |
Why?
|
| Gene Expression Profiling | 1 | 2024 | 1679 | 0.040 |
Why?
|
| Neoplasm, Residual | 1 | 2016 | 121 | 0.030 |
Why?
|
| Nitric Oxide | 1 | 2018 | 440 | 0.030 |
Why?
|
| Clinical Decision-Making | 1 | 2017 | 265 | 0.030 |
Why?
|
| Quality of Life | 1 | 2024 | 1932 | 0.030 |
Why?
|
| Dose-Response Relationship, Drug | 1 | 2018 | 1686 | 0.030 |
Why?
|
| Transcriptome | 1 | 2017 | 903 | 0.020 |
Why?
|
| Remission Induction | 1 | 2010 | 300 | 0.020 |
Why?
|
| Leg | 1 | 2010 | 155 | 0.020 |
Why?
|
| Scalp | 1 | 2010 | 56 | 0.020 |
Why?
|
| Face | 1 | 2010 | 180 | 0.020 |
Why?
|
| Follow-Up Studies | 1 | 2016 | 5050 | 0.020 |
Why?
|
| Time Factors | 1 | 2010 | 6228 | 0.010 |
Why?
|